CTRI/2014/01/004277
Completed
未知
A Prospective, Double Blind, Randomised, Two Arm, Placebo Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Two Proprietary Herbal Medicines as Mono Therapy and as Combination Therapy in Adult Subjects with Moderate to Severe Psoriasis.
Dr JRKs Siddha Research and Pharmaceuticals Private Limited0 sites42 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: L409- Psoriasis, unspecified
- Sponsor
- Dr JRKs Siddha Research and Pharmaceuticals Private Limited
- Enrollment
- 42
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Male and Female Adults between the ages of 18 and 50\.
- •2\.Psoriasis Body Surface Area at baseline is between \>\=3%
- •3\.Subject who understand and willing to sign informed consent document before start of any study specific assessment.
- •4\.Subjects who are willing not to participate in any other clinical trial during participation in the current trial.
- •5\.Subject has not participated in a similar investigation in the past four weeks.
Exclusion Criteria
- •1\.Subjects with Psoriatic Arthritis.
- •2\.Ongoing topical treatment or remedial measures for psoriasis inclusive of creams, lotions and oils 2 weeks before inclusion into the study.
- •3\.Subjects currently receiving drugs like Lithium, B\- blockers, Antimalarials and NSAIDs or using corticosteroids and anti\-inflammatory medicines until 15 days before inclusion into the study.
- •4\.Subjects are using DMARDS or are on Psoralen\+UVA \- Phototherapy 4 weeks prior to inclusion into the study.
- •5\.Subject with history of cancer including skin cancer.
- •6\.Subject with serious dermatological infection in past three months requiring systemic therapy.
- •7\.Subjects with facial melasma, lesions and other types of skin damage that is not psoriasis.
- •8\.History of or ongoing uncontrolled bacterial, viral, fungal, or atypical mycobacterial infection.
- •9\.History of opportunistic infections (e.g., systemic fungal infections, parasites)
- •10\.Any underlying uncontrolled medical illness including diabetes mellitus, hypertension, liver disease or history of alcoholism, HIV, hepatitis, severe cardiovascular, pulmonary, (especially COPD where steroid treatment is required), cerebral, hematologic, neurological or psychiatric disease.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Clinical study of JPT-25 capsules in people with smoking habitsHealth Condition 1: null- SmokersCTRI/2017/06/008787Gurseet Singh103
Recruiting
Phase 3
To evaluate the safety and efficacy of Liv.52 tablets in alcoholic patientsCTRI/2022/07/044203Himalaya Wellness Company
Active, not recruiting
Phase 1
A study to compare if 30mg of oral Dydrogesterone is as good, tolerable and safe as 600mg of intravaginal capsules for luteal support in IVF pregnancies. This study will be conducted at several study sites and neither the patient or the doctor will know which of the two different treatments a patient will receive.Female infertilityMedDRA version: 14.1Level: LLTClassification code 10003540Term: Assisted fertilizationSystem Organ Class: 100000004865Therapeutic area: Body processes [G] - Reproductive physiologi cal processes [G08]EUCTR2012-002215-26-ESAbbott Laboratories GmbH1,066
Active, not recruiting
Phase 1
A study to compare if 30mg of oral Dydrogesterone is as good, tolerable and safe as 600mg of intravaginal capsules for luteal support in IVF pregnancies. This study will be conducted at several study sites and neither the patient or the doctor will know which of the two different treatments a patient will receive.Female infertilityMedDRA version: 15.1Level: LLTClassification code 10003540Term: Assisted fertilizationSystem Organ Class: 100000004865Therapeutic area: Body processes [G] - Reproductive physiologi cal processes [G08]EUCTR2012-002215-26-BEAbbott Laboratories GmbH1,066
Active, not recruiting
Phase 1
A study to compare if 30mg of oral Dydrogesterone is as good, tolerable and safe as 600mg of intravaginal capsules for luteal support in IVF pregnancies. This study will be conducted at several study sites and neither the patient or the doctor will know which of the two different treatments a patient will receive.Female infertilityMedDRA version: 19.0Level: LLTClassification code 10003540Term: Assisted fertilizationSystem Organ Class: 100000004865Therapeutic area: Body processes [G] - Reproductive physiologi cal processes [G08]EUCTR2012-002215-26-ATAbbott Laboratories GmbH1,066